Literature DB >> 34985999

Vaccine-Associated Enhanced Respiratory Disease following Influenza Virus Infection in Ferrets Recapitulates the Model in Pigs.

J Brian Kimble1, Meghan Wymore Brand1, Bryan S Kaplan1, Phillip Gauger2, Elizabeth M Coyle3, Katarina Chilcote3, Surender Khurana3, Amy L Vincent1.   

Abstract

Influenza A virus (IAV) causes respiratory disease in swine and humans. Vaccines are used to prevent influenza illness in both populations but must be frequently updated due to rapidly evolving strains. Mismatch between the circulating strains and the strains contained in vaccines may cause loss of efficacy. Whole inactivated virus (WIV) vaccines with adjuvant, utilized by the swine industry, are effective against antigenically similar viruses; however, vaccine-associated enhanced respiratory disease (VAERD) may happen when the WIV is antigenically mismatched with the infecting virus. VAERD is a repeatable model in pigs, but had yet to be experimentally demonstrated in other mammalian species. We recapitulated VAERD in ferrets, a standard benchmark animal model for studying human influenza infection, in a direct comparison to VAERD in pigs. Both species were vaccinated with WIV with oil-in-water adjuvant containing a δ-1 H1N2 (1B.2.2) derived from the pre-2009 human seasonal lineage, then challenged with a 2009 pandemic H1N1 (H1N1pdm09, 1A.3.3.2) 5 weeks after vaccination. Nonvaccinated and challenged groups showed typical signs of influenza disease, but the mismatched vaccinated and challenged pigs and ferrets showed elevated clinical signs, despite similar viral loads. VAERD-affected pigs exhibited a 2-fold increase in lung lesions, while VAERD-affected ferrets showed a 4-fold increase. Similar to pigs, antibodies from VAERD-affected ferrets preferentially bound to the HA2 domain of the H1N1pdm09 challenge strain. These results indicate that VAERD is not limited to pigs, as demonstrated here in ferrets, and the need to consider VAERD when evaluating new vaccine platforms and strategies. IMPORTANCE We demonstrated the susceptibility of ferrets, a laboratory model species for human influenza A virus research, to vaccine-associated enhanced respiratory disease (VAERD) using an experimental model previously demonstrated in pigs. Ferrets developed clinical characteristics of VAERD very similar to that in pigs. The hemagglutinin (HA) stalk is a potential vaccine target to develop more efficacious, broadly reactive influenza vaccine platforms and strategies. However, non-neutralizing antibodies directed toward a conserved epitope on the HA stalk induced by an oil-in-water, adjuvanted, whole influenza virus vaccine were previously shown in VAERD-affected pigs and were also identified here in VAERD-affected ferrets. The induction of VAERD in ferrets highlights the potential risk of mismatched influenza vaccines for humans and the need to consider VAERD when designing and evaluating vaccine strategies.

Entities:  

Keywords:  VAERD; adjuvant; adjuvants; human; influenza; swine; vaccines

Mesh:

Substances:

Year:  2022        PMID: 34985999      PMCID: PMC8906406          DOI: 10.1128/JVI.01725-21

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   6.549


  53 in total

1.  MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines.

Authors:  Surender Khurana; Nitin Verma; Jonathan W Yewdell; Anne Katrin Hilbert; Flora Castellino; Maria Lattanzi; Giuseppe Del Giudice; Rino Rappuoli; Hana Golding
Journal:  Sci Transl Med       Date:  2011-06-01       Impact factor: 17.956

2.  ENHANCEMENT OF THE INFECTIVITY OF ARBOVIRUSES BY SPECIFIC ANTISERA PRODUCED IN DOMESTIC FOWLS.

Authors:  R A HAWKES
Journal:  Aust J Exp Biol Med Sci       Date:  1964-08

3.  Immunological enhancement of dengue virus replication.

Authors:  S B Halstead; J S Chow; N J Marchette
Journal:  Nat New Biol       Date:  1973-05-02

4.  Enhanced pneumonia and disease in pigs vaccinated with an inactivated human-like (δ-cluster) H1N2 vaccine and challenged with pandemic 2009 H1N1 influenza virus.

Authors:  Phillip C Gauger; Amy L Vincent; Crystal L Loving; Kelly M Lager; Bruce H Janke; Marcus E Kehrli; James A Roth
Journal:  Vaccine       Date:  2011-02-23       Impact factor: 3.641

5.  Transmissibility of variant influenza from Swine to humans: a modeling approach.

Authors:  Karen K Wong; Manoj Gambhir; Lyn Finelli; David L Swerdlow; Stephen Ostroff; Carrie Reed
Journal:  Clin Infect Dis       Date:  2013-07       Impact factor: 9.079

6.  Failure of protection and enhanced pneumonia with a US H1N2 swine influenza virus in pigs vaccinated with an inactivated classical swine H1N1 vaccine.

Authors:  Amy L Vincent; Kelly M Lager; Bruce H Janke; Marie R Gramer; Juergen A Richt
Journal:  Vet Microbiol       Date:  2007-07-17       Impact factor: 3.293

7.  Hemagglutinin inhibition assay with swine sera.

Authors:  Pravina Kitikoon; Phillip C Gauger; Amy L Vincent
Journal:  Methods Mol Biol       Date:  2014

8.  High titer and avidity of nonneutralizing antibodies against influenza vaccine antigen are associated with severe influenza.

Authors:  Kelvin K W To; Anna J X Zhang; Ivan F N Hung; Ting Xu; Whitney C T Ip; Rebecca T Y Wong; Joseph C K Ng; Jasper F W Chan; Kwok-Hung Chan; Kwok-Yung Yuen
Journal:  Clin Vaccine Immunol       Date:  2012-05-09

9.  Repeat vaccination reduces antibody affinity maturation across different influenza vaccine platforms in humans.

Authors:  Surender Khurana; Megan Hahn; Elizabeth M Coyle; Lisa R King; Tsai-Lien Lin; John Treanor; Andrea Sant; Hana Golding
Journal:  Nat Commun       Date:  2019-07-26       Impact factor: 14.919

10.  ISU FLUture: a veterinary diagnostic laboratory web-based platform to monitor the temporal genetic patterns of Influenza A virus in swine.

Authors:  Michael A Zeller; Tavis K Anderson; Rasna W Walia; Amy L Vincent; Phillip C Gauger
Journal:  BMC Bioinformatics       Date:  2018-11-01       Impact factor: 3.169

View more
  1 in total

1.  Development of a next-generation chikungunya virus vaccine based on the HydroVax platform.

Authors:  Dawn K Slifka; Hans-Peter Raué; Whitney C Weber; Takeshi F Andoh; Craig N Kreklywich; Victor R DeFilippis; Daniel N Streblow; Mark K Slifka; Ian J Amanna
Journal:  PLoS Pathog       Date:  2022-07-05       Impact factor: 7.464

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.